You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Muscle Invasive or Metastatic

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Bladder Cancer Trial in Tianjin (Cadonilimab)

Recruiting
  • Bladder Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Aug 23, 2023

Muscle Invasive Bladder Carcinoma Trial (FL-101)

Withdrawn
  • Muscle Invasive Bladder Carcinoma
  • (no location specified)
Aug 17, 2022

Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Malignant Urinary System Tumor Trial in Houston (procedure,

Active, not recruiting
  • Bladder Urothelial Carcinoma
  • +4 more
  • Biopsy
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 18, 2022

Muscle-Invasive Bladder Carcinoma Trial in Roma (Nivolumab, Nab paclitaxel, Cisplatin)

Not yet recruiting
  • Muscle-Invasive Bladder Carcinoma
  • Roma, Italy
    Roberto iacovelli
Jan 10, 2022

Invasive Bladder Cancer Trial in Sutton (Pembrolizumab, Radiotherapy)

Recruiting
  • Invasive Bladder Cancer
  • Sutton, United Kingdom
    NIHR Biomedical Research Centre at RM and ICR (https://www.cance
Apr 16, 2021

Muscle-Invasive Bladder Carcinoma, Oligometastatic Disease Trial (metastasis directed therapy (MDT), Immunotherapy)

Recruiting
  • Muscle-Invasive Bladder Carcinoma
  • Metastasis directed therapy (MDT)
  • +2 more
  • Ghent, Belgium
    Ghent University Hospital
Dec 3, 2022

Muscle-Invasive Bladder Carcinoma, Chemo Effect, Surgery Trial in Rome (cisplatin based neoadjuvant chemo, Radical cystectomy

Recruiting
  • Muscle-Invasive Bladder Carcinoma
  • +2 more
  • cisplatin based neoadjuvant chemotherapy
  • Radical cystectomy alone
  • Rome, Italy
    Riccardo Mastroianni
Mar 8, 2023

High-risk Non-muscle Invasive Bladder Cancer Trial (SHR-2005)

Not yet recruiting
  • High-risk Non-muscle Invasive Bladder Cancer
  • (no location specified)
Oct 25, 2023

Non-muscle Invasive Bladder Cancer Trial in Chengdu (RC48-ADC)

Not yet recruiting
  • Non-muscle Invasive Bladder Cancer
  • Chengdu, Sichuan, China
    West China Hospital
Aug 10, 2023

Bladder Cancer, Metastatic Bladder Cancer, Urothelial Carcinoma Trial in United States (Atezolizumab, Gemcitabine, Cisplatin)

Active, not recruiting
  • Bladder Cancer
  • +2 more
  • Hartford, Connecticut
  • +10 more
Nov 23, 2022

Muscle Invasive Bladder Urothelial Carcinoma Trial in Saint Louis (Daily Adaptive External Beam Radiation Therapy)

Not yet recruiting
  • Muscle Invasive Bladder Urothelial Carcinoma
  • Daily Adaptive External Beam Radiation Therapy
  • Saint Louis, Missouri
    Washington University, St. Louis
Jan 17, 2023

Muscle-invasive Bladder Cancer Based on PTC Drug Sensitivity

Recruiting
  • Muscle-Invasive Bladder Carcinoma
  • Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Mar 11, 2023

Tool in Non-muscle Invasive Bladder Cancer (NMIBC)

Not yet recruiting
  • Non-muscle-invasive Bladder Cancer
    • (no location specified)
    Apr 11, 2023

    Muscle Invasive Bladder Carcinoma Trial in Beijing (RC48-ADC, AK104)

    Recruiting
    • Muscle Invasive Bladder Carcinoma
    • Beijing, China
      Cancer Institute and Hospital, Chinese Academy of Medical Scienc
    Oct 6, 2023

    Uromonitor asBiomarker for Optimization of NMIBC Management by

    Not yet recruiting
    • Non-muscle-invasive Bladder Cancer
      • (no location specified)
      May 9, 2023

      Neutrophils to Lymphocytes Ratio in Predicting Response to BCG

      Completed
      • Urinary Bladder Cancer
      • +4 more
      • Neutrophil to lymphocyte ratio
      • Cairo, Egypt
        Ain Shams university
      Jul 15, 2023

      Non-Muscle- Invasive Bladder Cancer Trial (Durvalumab, BCG)

      Not yet recruiting
      • Non-Muscle- Invasive Bladder Cancer
      • Durvalumab
      • BCG
      • (no location specified)
      Jul 5, 2023

      Nivolumab in Japanese Muscle-invasive Urothelial Carcinoma

      Not yet recruiting
      • Muscle-invasive Urothelial Carcinoma
        • City, State, Japan
          Local Institution
        Mar 20, 2023

        Bladder Cancer Trial in Jinan (Pseudomonas aeruginosa)

        Recruiting
        • Bladder Cancer
        • Pseudomonas aeruginosa
        • Jinan, Shandong, China
          Qilu hospital
        Jul 26, 2023

        Non-muscle-invasive Bladder Cancer Trial (Cystoscopy, Bladder EpiCheck urine test, Xpert Bladder Cancer Monitor urine test)

        Not yet recruiting
        • Non-muscle-invasive Bladder Cancer
        • Cystoscopy
        • +2 more
        • (no location specified)
        Apr 4, 2023

        Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive

        Recruiting
        • Non Muscle Invasive Bladder Cancer
        • N803 plus Bacillus Calmette-Guerin (BCG)
        • Honolulu, Hawaii
          Island Urology
        Aug 7, 2023

        Non-muscle-invasive Bladder Cancer Trial in Shanghai (BCG combined with Tislelizumab)

        Not yet recruiting
        • Non-muscle-invasive Bladder Cancer
        • BCG combined with Tislelizumab
        • Shanghai, Shanghai, China
          Ruijin Hospital, Shanghai Jiaotong University School of Medicine
        Oct 12, 2022

        Non-Muscle Invasive Bladder Cancer, HER2 Trial (RC48, Tislelizumab)

        Not yet recruiting
        • Non-Muscle Invasive Bladder Cancer
        • HER2
        • (no location specified)
        Jul 16, 2023

        Non-muscle Invasive Bladder Cancer Trial (TARA-002)

        Not yet recruiting
        • Non-muscle Invasive Bladder Cancer
        • TARA-002
        • (no location specified)
        Jul 14, 2023

        Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8 Trial in Seattle (Best

        Not yet recruiting
        • Muscle Invasive Bladder Carcinoma
        • +2 more
        • Best Practice
        • +6 more
        • Seattle, Washington
          Fred Hutch/University of Washington Cancer Consortium
        Sep 18, 2023